Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Mislabeled ibuprofen, seizure drugs recalled

Posted: July 24, 2014

American Health Packaging (AHP) is recalling packages of the anti-inflammatory drug ibuprofen and the anti-seizure drug oxcarbazepine because the individual blister packs may be mislabeled and contain the wrong drug. Thus, patients prescribed oxcarbazepine may inadvertently take a dose of

Long-term use of antipsychotic Risperdal in children linked to reduced bone mass

Posted: July 24, 2014

Long-term use of the antipsychotic drug Risperdal in children can reduce bone mass and prevent bone growth, according to a new study presented at the American Society of Clinical Psychopharmacology’s annual meeting. Similar results were found in children treated long-term

Mental anguish from gynecomastia can last decades

Posted: July 23, 2014

Lorne Jaffe, a stay-at-home dad and blogger for the Huffington Post describes life with gynecomastia, a condition in which adolescent boys grow breasts, this way: “I grew up a seemingly normal, slightly chubby boy who by age 11 had a

Adherence to statin therapy linked to increased risk of type 2 diabetes

Posted: July 23, 2014

People who adhere to statin therapy to lower their cholesterol levels and reduce their risk for cardiovascular disease are at greater risk of developing new-onset type 2 diabetes, according to a study published in the journal Diabetes Care.

Controversial analysis suggests Actos may help protect users from dementia

Posted: July 22, 2014

The type 2 diabetes drug Actos could help ward off dementia, a new analysis has found. However, researcher say more analysis is needed as well as adverse side effects addressed before the medication can be recommended as a preventative measure.

Transvaginal mesh lawsuits continue three years after FDA warning

Posted: July 22, 2014

It has been three years since the Food and Drug Administration (FDA) issued a Safety Communication warning the public that complications with transvaginal mesh used to treat pelvic floor disorders including pelvic organ prolapse and stress urinary incontinence were not

Lipitor side effects lawsuits mounting against Pfizer

Posted: July 22, 2014

Lawsuits have been mounting against drugmaker Pfizer alleging the company failed to warn the public that its top selling cholesterol-lowering statin Lipitor could cause type 2 diabetes.

Hormonal contraceptives may increase risk of gestational diabetes

Posted: July 21, 2014

Women who use contraceptives that contain hormones before they become pregnant may be at greater risk for developing gestational diabetes once they do get pregnant, according to a new study.

Pre-diabetes diagnoses benefit drug companies more than patients

Posted: July 20, 2014

Non-diabetics with higher-than-recommended blood sugar levels and thus at risk for developing type 2 diabetes are considered pre-diabetic, however classifying large numbers of people with pre-diabetes offers more benefit to drug companies than those diagnosed with the condition, researchers argue.

New blood clot warning added to safety labels of testosterone replacement therapies

Posted: July 20, 2014

The safety labels of testosterone replacement treatments have been updated to include warnings of an increased risk of life threatening blood clots. The update comes on the heels of a Food and Drug Administration (FDA) safety alert notifying the public